Overview
- The FDA approved Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes on Friday, August 28, 2026.
- The decision rests on the SURPASS‑CVOT trial, which enrolled about 13,299 people across roughly 640 sites and showed tirzepatide met noninferiority versus dulaglutide with an estimated 8% lower risk and a hazard ratio of about 0.92.
- Major adverse cardiovascular events in the trial refer to cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, outcomes the approval specifically addresses.
- Safety in the trial matched prior experience: most adverse events were gastrointestinal, typically mild to moderate during dose escalation, but the label keeps warnings for thyroid tumors, pancreatitis, hypoglycemia, kidney problems and severe allergic reactions.
- The new indication immediately boosts Eli Lilly’s commercial position and produced a modest stock rebound, while regulators and clinicians say continued active surveillance and longer randomized follow‑ups remain important given accumulating spontaneous adverse reports such as the UK Yellow Card submissions.